Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2017 2
2019 1
2020 6
2021 5
2022 4
2023 0
Text availability
Article attribute
Article type
Publication date

Search Results

17 results
Results by year
Filters applied: . Clear all
Page 1
Induction chemoimmunotherapy followed by CD8+ immune cell-based patient selection for chemotherapy-free radioimmunotherapy in locally advanced head and neck cancer.
Hecht M, Eckstein M, Rutzner S, von der Grün J, Illmer T, Klautke G, Laban S, Hautmann MG, Brunner TB, Tamaskovics B, Hinke A, Zhou JG, Frey B, Donaubauer AJ, Becker I, Semrau S, Hartmann A, Balermpas P, Budach W, Gaipl US, Iro H, Gostian AO, Fietkau R. Hecht M, et al. Among authors: rutzner s. J Immunother Cancer. 2022 Jan;10(1):e003747. doi: 10.1136/jitc-2021-003747. J Immunother Cancer. 2022. PMID: 35078923 Free PMC article. Clinical Trial.
Transient Enlargement in Meningiomas Treated with Stereotactic Radiotherapy.
Maksoud Z, Schmidt MA, Huang Y, Rutzner S, Mansoorian S, Weissmann T, Bert C, Distel L, Semrau S, Lettmaier S, Eyüpoglu I, Fietkau R, Putz F. Maksoud Z, et al. Among authors: rutzner s. Cancers (Basel). 2022 Mar 17;14(6):1547. doi: 10.3390/cancers14061547. Cancers (Basel). 2022. PMID: 35326697 Free PMC article.
F18-FDG PET/CT imaging early predicts pathologic complete response to induction chemoimmunotherapy of locally advanced head and neck cancer: preliminary single-center analysis of the checkrad-cd8 trial.
Beck M, Hartwich J, Eckstein M, Schmidt D, Gostian AO, Müller S, Rutzner S, Gaipl US, von der Grün J, Illmer T, Hautmann MG, Klautke G, Döscher J, Brunner T, Tamaskovics B, Hartmann A, Iro H, Kuwert T, Fietkau R, Hecht M, Semrau S. Beck M, et al. Among authors: rutzner s. Ann Nucl Med. 2022 Jul;36(7):623-633. doi: 10.1007/s12149-022-01744-6. Epub 2022 May 10. Ann Nucl Med. 2022. PMID: 35534690 Free PMC article.
Questionnaire-based detection of immune-related adverse events in cancer patients treated with PD-1/PD-L1 immune checkpoint inhibitors.
Griewing LM, Schweizer C, Schubert P, Rutzner S, Eckstein M, Frey B, Haderlein M, Weissmann T, Semrau S, Gostian AO, Müller SK, Traxdorf M, Iro H, Zhou JG, Gaipl US, Fietkau R, Hecht M. Griewing LM, et al. Among authors: rutzner s. BMC Cancer. 2021 Mar 24;21(1):314. doi: 10.1186/s12885-021-08006-0. BMC Cancer. 2021. PMID: 33761922 Free PMC article.
Implementation of Double Immune Checkpoint Blockade Increases Response Rate to Induction Chemotherapy in Head and Neck Cancer.
Semrau S, Gostian AO, Traxdorf M, Eckstein M, Rutzner S, von der Grün J, Illmer T, Hautmann M, Klautke G, Laban S, Brunner T, Tamaskovics B, Frey B, Zhou JG, Geppert CI, Hartmann A, Balermpas P, Budach W, Gaipl U, Iro H, Fietkau R, Hecht M. Semrau S, et al. Among authors: rutzner s. Cancers (Basel). 2021 Apr 19;13(8):1959. doi: 10.3390/cancers13081959. Cancers (Basel). 2021. PMID: 33921668 Free PMC article.
Prospective development and validation of a liquid immune profile-based signature (LIPS) to predict response of patients with recurrent/metastatic cancer to immune checkpoint inhibitors.
Zhou JG, Donaubauer AJ, Frey B, Becker I, Rutzner S, Eckstein M, Sun R, Ma H, Schubert P, Schweizer C, Fietkau R, Deutsch E, Gaipl U, Hecht M. Zhou JG, et al. Among authors: rutzner s. J Immunother Cancer. 2021 Feb;9(2):e001845. doi: 10.1136/jitc-2020-001845. J Immunother Cancer. 2021. PMID: 33593828 Free PMC article.
Predictive Value of Multiparametric MRI for Response to Single-Cycle Induction Chemo-Immunotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma.
Hellwig K, Ellmann S, Eckstein M, Wiesmueller M, Rutzner S, Semrau S, Frey B, Gaipl US, Gostian AO, Hartmann A, Iro H, Fietkau R, Uder M, Hecht M, Bäuerle T. Hellwig K, et al. Among authors: rutzner s. Front Oncol. 2021 Oct 21;11:734872. doi: 10.3389/fonc.2021.734872. eCollection 2021. Front Oncol. 2021. PMID: 34745957 Free PMC article.
17 results